An analysis of safety data suggests that Abrysvo, the Pfizer respiratory syncytial virus (RSV) RSVpreF vaccine, does not increase the risk of adverse pregnancy outcomes when administered after 32 weeks’ gestation, according…
Pfizer’s RSV vaccine safe to use during pregnancy, study suggests
